Navigation Links
Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results
Date:5/9/2011

MISSISSAUGA, Ontario, May 9, 2011 /PRNewswire/ --

  • 2011 First Quarter Total Revenue $565 million, including $36 million related to out-license of Cloderm
  • Pro forma organic growth for the combined company, excluding the impact of foreign exchange and acquisitions, was approximately 7%
  • Excluding impact from Diastat and Efudex, pro forma organic growth for the combined company was approximately 11%
  • 2011 First Quarter GAAP EPS $0.02; Cash EPS $0.62
  • Excluding impact from Cloderm out-licensing, Cash EPS was $0.56
  • 2011 First Quarter GAAP Cash Flow from Operations was $86 million; Adjusted Cash Flow from Operations was $204 million  
  • 2011 Guidance increased to $2.65 - $2.90 Cash EPS

  • Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announces first quarter financial results for 2011.

    "Our performance in the first quarter is a strong start to what I believe will be another successful year for Valeant," said J. Michael Pearson, chairman and chief executive officer.  "Our specialty businesses performed well and our branded generic operations, in particular Central Europe, exceeded our expectations this quarter.  This strong performance is a testament to our diversified business model that gives us the ability to pursue acquisition opportunities, while continuing to deliver strong operating results."

    RevenueTotal revenue was $565.0 million in the first quarter of 2011 as compared to $219.6 million in the first quarter of 2010.  Included in total revenue was $36.0 million of alliance and royalty revenue related to the out-license of product rights for Cloderm, a mid-potency steroid with an annual revenue run rate of approximately $7 million, that was completed on March 31, 2011.  Product sales were $500.4 million in the fi
    '/>"/>

    SOURCE Valeant Pharmaceuticals International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Valeant to Acquire Polish Products
    2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
    3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
    4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
    5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
    6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
    7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
    8. Valeant Announces Pricing of Senior Notes
    9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
    10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
    11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... 2014  Houston dentist , Dr. ... treatment with Invisalign. With access to this increasingly ... teeth straightened without feeling self-conscious in the process. ... other types of braces, but patients who choose ... to better support for their oral health and ...
    (Date:7/28/2014)... , 28 luglio 2014 ResMed (NYSE: ... prodotti per la cura dei disturbi respiratori del sonno ... avuto un,ingiunzione permanente in Germania contro il produttore Taiwanese ... la vendita di apparecchiature da indossare in testa, che ... le maschere 220. La sentenza della Corte Regionale Distrettuale ...
    (Date:7/28/2014)... 2014 OmPrompt gab ... £ investiert hat, um die weltweite Nachfrage ... und Logistikbranche zu erfüllen. Albion wird Teil ... http://photos.prnewswire.com/prnh/20140728/697982 ) In ... beschleunigtes Wachstum mit Investitionen in seine Plattform, ...
    Breaking Medicine Technology:Houston Cosmetic Dentist, Dr. Behzad Nazari, Now Offers Orthodontic Treatment with Invisalign 2ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2
    (Date:7/28/2014)... Medicine (BUSM) report variants in a new gene, PLXNA4, ... (AD). The discovery of this novel genetic association may ... specifically. These findings appear in the Annals of ... dementia affecting 5.4 million Americans including 13 percent of ... percent of people age 85 and older. Genetic factors ...
    (Date:7/28/2014)... WA (PRWEB) July 28, 2014 ... consulting and care management organizations, has published a ... low-cost approach to engaging patients and families in ... environments at multiple hospitals, the toolkit provides a ... huddle” with patients and their families early in ...
    (Date:7/28/2014)... America Carotenoids & Antioxidants Market report defines and segments the ... forecast of revenue. This market is estimated to grow from ... at a CAGR of 7.1% from 2013 to 2018. , ... Antioxidants Market report to get an idea of the in-depth ... in the market, and is supported by various tables and ...
    (Date:7/28/2014)... MONDAY, July 28, 2014 (HealthDay News) -- People with ... for obesity and diabetes, a new study suggests. ... that brown fat actually improves insulin sensitivity, blood sugar ... for overweight and obese people," Labros Sidossis, a professor ... at the University of Texas Medical Branch at Galveston, ...
    (Date:7/28/2014)... 2014A two-step decision tree analysis, incorporating Donabedian,s model, ... the many available quality standards, guidelines, recommendations and ... international quality standards for radiation therapy, according to ... of Practical Radiation Oncology (PRO), the ... for Radiation Oncology (ASTRO). , Guidelines, recommendations and ...
    Breaking Medicine News(10 mins):Health News:Researchers identify potential biomarker for AD 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Healthy 'Brown Fat' May Cut Odds for Obesity, Diabetes 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3
    ... Dental Service Building for Early Childhood Oral Health at ... to provide 30,000 patient visits annually, SEATTLE, Nov. ... and Children,s Hospital and Regional Medical Center,today announced they ... dental disease with the development of a new pediatric ...
    ... and Reject ... Ramius, Opposition Slate, MONTVALE, ... mailed the following letter to all shareholders from,Lawrence Saper, Chairman ... Company,s Annual Meeting of Shareholders scheduled for,Thursday, December 20, 2007. ...
    ... Wash., Nov. 16 CellCyte Genetics,Corporation (the ... Tony,Colasin as its Director of Business Development ... licensing efforts. Tony Colasin was former ... From January 2001 to January 2007, he ...
    ... gave up as he,battled corporate investors as they took over ... him about greed and ethics,"isn,t the kind of thing you ... education to good use, pulling together an,experienced management team this ... juice drink for school-aged children. As co-founder and CEO ...
    ... Neutrogena(R), a worldwide leader,in the development of highly ... Diane Lane has signed on to be,an ambassador ... captivating and inspiring actress who personifies the,Neutrogena(R) brand ... her new,role, she will be featured in national ...
    ... rate between 0 and 2.6% (average 0.3%) in general population. ... tolerated by patients, causing a delay in medical consultation. Together ... with diagnosis and treatment of tinea of the nails. , ... the nails was observed in the Hospital del Mar Pediatric ...
    Cached Medicine News:Health News:$5 M Gift Boosts Childhood Oral Health Care Offered by UW, Children's Hospital 2Health News:Datascope Mails Letter to Shareholders 2Health News:Datascope Mails Letter to Shareholders 3Health News:Datascope Mails Letter to Shareholders 4Health News:Datascope Mails Letter to Shareholders 5Health News:Datascope Mails Letter to Shareholders 6Health News:Datascope Mails Letter to Shareholders 7Health News:Datascope Mails Letter to Shareholders 8Health News:CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development 2Health News:CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development 3Health News:CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development 4Health News:Fruit 66 Creator Takes the High Road to Create a Healthy Drink for Students 2Health News:Oscar-Nominated Actress Signs on as Neutrogena(R) Brand Ambassador 2Health News:Tinea of the nails underdiagnosed in children 2
    Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
    Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
    Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
    Kleinert-Kutz Single Skin Hook, Large...
    Medicine Products: